Sanofi (EURONEXT: SAN) announced Wednesday that its investigational therapy, efdoralprin alfa, has received orphan drug ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...

EMA grants orphan designation to Sanofi’s efdoralprin alfa for alpha-1 antitrypsin deficiency related emphysema: Paris Thursday, December 18, 2025, 13:00 Hrs [IST] Sanofi, an R& ...

Shares of FibroGen, Inc. (NASDAQ:FGEN) climbed about 3% on Monday after the company said its drug candidate roxadustat has ...

GSK plc GSK announced that the FDA has granted Orphan Drug Designation to GSK’227, its investigational B7-H3-targeted ...

Investing.com -- FibroGen, Inc. (NASDAQ:FGEN) stock rose 3% Monday after the company announced that its drug roxadustat received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA ...

As orphan drugs account for an increasing share of drugs approved, they are driving up the cost of drug launches and drug prices. In a new paper, America's Health Insurance Plans analyzes these rising ...

Optum is seeing an increase of new orphan drugs, and expects this trend to continue, if not accelerate, according to a drug pipeline report from the UnitedHealth Group subsidiary. What makes this ...

The Orphan Drug Act (ODA) came into effect in 1983 as a solution to meet an unmet need in the industry. Its success is often projected as an example of how innovative regulatory frameworks can be used ...

The Orphan Drug Act of 1983 was passed to promote the development of rare disease treatments. To qualify for incentives under the act, sponsors must first receive “orphan drug designation” from the ...

The IRA requires health plans serving the Part D market to cover all negotiated drugs, and it has been predicted that CMS ...

Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysemaAdditional orphan designation ...